Rat VSMCs were extracted from the aortas of six-week-old Sprague-Dawley male rats by using tissue adhesion methods. Blood vessels were cut out, and the fat, connective tissue and fibrous membrane were peeled off. The tissue was then cut into small pieces and transferred to a cell culture flask for overnight incubation with DMEM-F12 supplemented with 10% fetal bovine serum (FBS) in a humidified 5% CO2 atmosphere at 37 °C. Primary VSMCs between the 3rd and 6th passages were used for experiments. Human 293T cells were maintained in DMEM supplemented with 10% FBS in a humidified 5% CO2 atmosphere at 37 °C.
MiR-93 mimics, miR-93 inhibitors, antagomiR-93 and matched controls were purchased from RiboBio (Guangzhou, China). Mfn2 siRNA, Mfn2 pcDNA and matched controls were purchased from RiboBio (Guangzhou, China). Lipofectamine 2000 (Invitrogen, Waltham, MA, USA) was used to perform miRNA transfections according to the manufacturer's instructions. PDGF-BB (Sigma, St. Louis, MO, USA) was used in time and concentration gradient experiments to determine the final intervention dose.
MiR-93 mimics, miR-93 inhibitors, antagomiR-93 and matched controls were purchased from RiboBio (Guangzhou, China). Mfn2 siRNA, Mfn2 pcDNA and matched controls were purchased from RiboBio (Guangzhou, China). Lipofectamine 2000 (Invitrogen, Waltham, MA, USA) was used to perform miRNA transfections according to the manufacturer's instructions. PDGF-BB (Sigma, St. Louis, MO, USA) was used in time and concentration gradient experiments to determine the final intervention dose.